The Pharmaceutical Industry Records Major Milestones With New Insmed and Eli Lilly Treatments
- Feb 19
- 2 min read
The pharmaceutical industry is experiencing significant milestones this week, marked by audacious sales projections and unprecedented clinical trial results. Two major developments are turning heads: Insmed's highly successful launch of its new respiratory drug, and Eli Lilly's innovative approach to treating co-occurring skin and weight conditions.
Insmed CEO Will Lewis has confidently projected that Brinsupri, a newly approved respiratory drug, will reach $1 billion in revenue in 2026. While Lewis himself called the forecast "audacious," the numbers back it up: following its August approval, fourth-quarter sales hit an impressive $145 million, a figure analysts called a "ginormous result". Brinsupri is a first-in-class dipeptidyl peptidase 1 (DPP1) inhibitor used to treat non-cystic fibrosis bronchiectasis (NCFBE).
The company originally based its $5 billion peak sales estimate on a target population of 250,000 U.S. patients. However, Insmed expects this market to grow significantly as physicians better identify the disease and transition misdiagnosed asthma or COPD patients to Brinsupri. While U.S. sales soar, international launches in Europe and Japan remain paused as the company awaits clarity on the impacts of Most Favored Nation (MFN) drug pricing policies.
Meanwhile, Eli Lilly and Company reported highly positive results from its Phase 3b trials evaluating the concomitant use of its psoriasis drug Taltz and its weight-loss medication Zepbound. The TOGETHER-PsO study tested adults suffering from both moderate-to-severe plaque psoriasis and obesity or overweight.
The results were striking: at 36 weeks, 27.1% of patients receiving both Taltz and Zepbound achieved complete skin clearance and at least a 10% weight loss, compared to only 5.8% of patients taking Taltz alone. This combined approach directly addresses the compounded burden of these conditions, as approximately 61% of U.S. psoriasis patients also struggle with obesity or overweight. Lilly noted that the trial participants faced a very high burden of disease, with an average BMI of over 39 kg/m². A related study also showed parallel success for patients with psoriatic arthritis, further cementing the benefits of targeting shared inflammatory pathways with dual therapy.
🔖 Sources
Keywords: Pharmaceutical Industry
Pharmaceutical Industry
Comments